Oncology Best Practice™ Grand Rounds Series: What the Community Needs to Know to Apply RLT in PSMA-Positive mCRPC in Context with Current Treatment Paradigms
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com
Upcoming Sessions:
Overview
Although it is curable, the recurrence rate of prostate cancer following curative-intent treatment is nearly 50% of patients in their first decade of treatment. Most men that are diagnosed with prostate cancer will not succumb to their disease, however, treatments are thus aimed at the direst conditions. To compound that issue, standard imaging to detect recurrence detection has a low sensitivity, especially in instances where the prostate-specific antigen (PSA) levels are low.
With these challenges in mind, PER presents this nationwide Oncology Best Practice™ series whereby regional live grand rounds/visiting speaker programs will be held in locations across the US. The goal of the program is to present new data snf clinical scenarios exploring the evidence behind treatment decisions. This will encourage faculty to engage in peer-to-peer and peer-to-expert interactions, as well as the sharing of best practices for the treatment of recurrent prostate cancer.
Target Audience
This educational activity is directed toward medical oncologists, radiologists, radiation oncologists, urologists, and other oncology healthcare professionals.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Outline the role of PSMA-PET/CT imaging in diagnosis and management of patients with prostate cancer, and best practices for detecting patients with PSMA-positive mCRPC
- Evaluate recent clinical trial evidence on PSMA-targeting strategies, including radioligand therapies and its implications on mCRPC treatment algorithm
- Discuss strategies for optimizing care of patients with PSMA-positive mCRPC by appropriately sequencing radioligand therapies and mitigating toxicities associated with radioligand therapies
- Explain barriers for diagnosis and management of PSMA-positive mCRPC and effective multidisciplinary care strategies to overcome these barriers
Faculty Presenter
Scott T. Tagawa, MD, MS FACP
Richard A. Stratton Associate Professor in Hematology and Oncology
Medical Director, GU Oncology Research Program
Associate Professor of Clinical Medicine and Urology
Weill Cornell Medicine
New York, NY
Accreditation/ Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation